



BEST AVAILABLE COPY

Attorney Docket No. 1623-U-05

1641

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Art Unit:

Serial No.: 09/966,311

Filing Date: 09/28/2001

Applicants: DAVID E. BERG, LOIS HILL BERG, and
HAROLD H. HARRISON

Title of Invention: METHOD FOR DETECTING PROCOAGULANT GENETIC
AND METABOLIC CONDITIONS ASSOCIATED WITH,
AND POTENTIALLY PREDISPOSITIONAL FOR,
ACTIVATION OF THE COAGULATION RESPONSE.

RECEIVED

MAR - 7 2002

TECH CENTER 1600/2900

Box PATENT APPLICATION - No Fee
Assistant Commissioner for Patents
Washington, DC 20231

CERTIFICATE OF MAILING

The undersigned certifies that the attached SUPPLEMENT TO
INFORMATION DISCLOSURE STATEMENT, together with this Certificate of
Mailing and a postcard is being deposited with the United States Postal Service as first
class mail in an envelope addressed to: Box PATENT APPLICATION - No Fee,
Assistant Commissioner for Patents, Washington, DC 20231, on February 5,
2002.

Dated this 5th day of February, 2002

Charles E. Cates

Charles E. Cates, Reg. No. 25,838
Karyn L. Osterman, Esq.
CATES & HOLLOWAY
P.O. Box 1532
Scottsdale, AZ 85252-1532
(602) 248-0982



BEST AVAILABLE COPY

#3
NW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:

Art Unit:

Serial No.: 09/966,311

Filing Date: 09/28/2001

Applicants: DAVID E. BERG, LOIS HILL BERG, and
HAROLD H. HARRISON

Title of Invention: METHOD FOR DETECTING PROCOAGULANT GENETIC
AND METABOLIC CONDITIONS ASSOCIATED WITH,
AND POTENTIALLY PREDISPOSITIONAL FOR,
ACTIVATION OF THE COAGULATION RESPONSE.

RECEIVED

MAR - 7 2002

TECH CENTER 1600/2900

Box PATENT APPLICATION - No Fee
Assistant Commissioner for Patents
Washington, DC 20231

**TRANSMITTAL OF SUPPLEMENT TO INFORMATION DISCLOSURE
STATEMENT**

The information disclosure statement was previously submitted on December 27, 2001 in compliance with 37 C.F.R. 1.97(b). One of the references was not available at that time. A copy of that cited reference is now enclosed.

The non patent literature document is by Bona, R., described as follows:
"Thrombin generation and activity are increased in patients with cancer receiving sodium warfarin as secondary prophylaxis against venous thrombosis."

This Supplement to the Information Disclosure Statement is being submitted by Charles E. Cates, attorney for applicant.

Dated this 5 day of February, 2002.

Respectfully submitted,
CATES & HOLLOWAY

By Charles E. Cates
Charles E. Cates
Registration No. 25,838
P. O. Box 1532
Scottsdale, Arizona 85252-1532
(602)248-0982